Clinical research founded on evidence‐based medicine is essential to improve cardiovascular outcomes.23 The inclusion of diverse patients in the evidence‐generation process is crucial to ensure the generalizability of results. Moreover, to ensure that population differences can be identified, sufficient patients from a variety of diverse population groups must be included in randomized controlled trials. Representation and detailed reporting of participant demographics are particularly pertinent in cardiovascular clinical trials due to differing risk profiles of population subgroups and potential sex‐, race‐, and ethnicity‐based variations in cardiovascular drug responses.24, 25, 26 These differences in CVD risk and outcomes between populations are of increasing importance with the advent of personalized approaches to cardiovascular risk estimation and treatment based on patients' lipid profiles, genetics, comorbidities, and other factors.27Reporting practices within randomized controlled trials can also mask population differences even if a representative population is included. For example, the practice of consolidating racial or ethnic groups into 1 major group (ie, Non‐White, or Other) has left many ethnic groups, and their associated cardiovascular risk factors and pharmacogenetic differences, overlooked.26, 28, 29, 30 Many pivotal statin studies did not report participant race or ethnicity data,31, 32, 33, 34 and, if included, race was listed only as White, Black, or Other.35 More recent studies show that Asian American ethnic subgroups have distinct patterns of dyslipidemia prevalence and subtype.28 South Asian individuals have higher atherosclerotic CVD mortality rates compared with other Asian groups and non‐Hispanic White individuals, in contrast to the finding that Asian American people aggregated as a group are at low risk of atherosclerotic CVD.26 Indeed, although the age‐standardized cardiovascular death rate of South Asian individuals exceeds global levels (278 versus 235 deaths/100 000, in 2021, respectively),36 this subgroup of >2 billion37 at‐risk people remains rarely specified in race statistics within cardiovascular research.By creating population‐specific knowledge gaps in the efficacy and safety of interventions,11, 12, 14 underrepresentation brings the integrity of evidence‐based care algorithms into question.29, 38 Cholesterol management guidelines have historically been based on male‐derived trial data, despite marked sex‐specific differences in the landscape of atherosclerosis,39 and evidence suggests that clinical research on predominantly White participants contributes to inequitable screening practices for cardiovascular risk factors, such as diabetes.40 Conversely, when diverse patient groups are included in research, this may promote awareness of, and trust in, novel therapies, increasing their uptake in underserved groups and decreasing the overall CVD burden.
BARRIERS TO REPRESENTATION OF UNDERSERVED GROUPS WITHIN CARDIOVASCULAR CLINICAL RESEARCH
Barriers to the participation of underserved groups within cardiovascular research remain (Figure 1).Randomized controlled trials typically have stringent criteria, favoring the enrollment of individuals with similar characteristics to decrease the effect of interindividual variabilities on study results. However, this methodology has inadvertently resulted in the systematic underrepresentation of populations at greatest risk,38, 41 and contrary to being an empirical necessity, exclusions are often rooted in structural racism.15 Overly restrictive criteria are often used in cardiovascular research without justification, such as excluding individuals with the use of any medication at baseline, physical disability, or necessitating contraceptive use for female participants regardless of the risk of pregnancy.42, 43 Although these criteria may not affect participant safety or study results, they prevent participation for medically underserved individuals. Similarly, participants in cardiovascular studies are often required to be maximally treated,12 resulting in the exclusion of individuals not meeting these criteria due to delays in diagnosis and reduced treatment access.23 Further, it may be the case that individuals with reduced access to health care are less likely to have known levels of biomarkers needed to qualify for a study screening visit, excluding them before they are even considered for participation.44 Costs associated with trial participation also obstruct the participation of underserved groups, and even with care covered by insurance, ill‐considered or time‐consuming reimbursement policies can hinder the enrollment of individuals of lower socioeconomic status.45, 46Randomized controlled trials are typically conducted at large academic centers47; even if underserved participants did wish to enroll, they may be unable or unwilling to access these sites due to cost burdens or a lack of transportation.11, 23 Further to travel time, many cardiovascular studies include study visits that can last several hours, for example, study Visit 1, in which screening, informed consent, medical history, physical exam, and other activities are completed. Undertaking studies at traditional research facilities can also suppress staff diversity,23, 30 and patients may be willing to participate in a trial only if their usual clinician is involved.48 Community‐based health care providers play a vital role in fostering trust within underserved communities, yet they are often unable to participate in clinical research.48, 49 Evidence from cardiologists, and physicians invited to oncology clinical trials, suggests barriers include a lack of the time, resources, and infrastructure needed to conduct research; role conflicts between physician and principal investigator (PI); inadequate research experience and training; and lack of rewards and recognition.49, 50 A PI's prior experience in similar studies is typically a main criterion for site selection, preventing the participation of many community‐based clinicians.Historic mistreatment, unethical research practices, and culturally insensitive care have resulted in endemic mistrust in the health care system among Black people51 and American Indian and Alaska Native communities,52 among others. Consequently, individuals from these groups may be unwilling to participate in clinical trials when given the opportunity to do so.48 In addition, traditional recruitment approaches may leave patients from underserved groups inappropriately overlooked or untargeted.15, 53, 54 In 5 clinical studies including patients with acute coronary syndrome, atrial fibrillation, and heart failure, failure to screen an adequate number of female participants and address barriers to women's enrollment were principal factors responsible for the low number of women enrolled.53 Lack of understanding of the potential risks and benefits of trial participation is another major cause of refusal,11, 12 suggesting that individuals with low health literacy are not effectively engaged with standard recruitment practices. Additionally, a lack of diversity and representation within the clinical trial team can result in a failure to consider cultural, language, and communication barriers.23, 30
OVERCOMING BARRIERS TO THE INCLUSION OF UNDERSERVED GROUPS
To facilitate the participation of underserved populations in clinical trials, coordinated, tailored, holistic approaches are necessary to overcome system‐ and individual‐level barriers to inclusion. Two such tactics to improve diversity in cardiovascular clinical research are decentralized clinical trials (DCTs) and community‐centered research approaches (Figure 2).AI indicates artificial intelligence; EMR, electronic medical record; and HCP, health care provider.DCTs are clinical trials in which some or all activities occur at locations other than a traditional study site, including the participant's home, local health care facilities, or nearby laboratories.55 The COVID‐19 pandemic accelerated the application of DCTs to allow the continuation of clinical research despite movement restrictions.47 As a result, DCTs have demonstrated large‐scale feasibility within the cardiovascular research paradigm; notable cardiovascular intervention studies that have incorporated decentralized approaches are summarized in the Table.56, 57, 58, 59, 60, 61Cardiovascular Intervention Studies Using Decentralized ApproachesA randomized controlled trial investigating whether statin initiation could increase survival free of dementia and disability in older adultsThe study design incorporates elements of direct‐to‐participant telehealth, including home delivery of study medication and remote follow‐up to dramatically reduce participant burden, maintain engagement, and reach diverse populations by aligning with the needs of the study populationThe scalable, decentralized design resulted in rapid recruitment, with high engagement and protocol adherenceAlthough participants in this trial were predominantly White, the authors acknowledged that their approach could be adapted to prioritize and ensure participant diversityThese innovations in remote study design can be harnessed to address barriers to the participation of underserved groups.47, 62 DCTs can overcome financial and logistical barriers caused by limited access to traditional study sites by allowing remote recruitment, screening, participation, and flexible visit schedules.47 Digital and wearable technologies may be leveraged based on how CVD is monitored,62 meaning remote participation and home monitoring could be incorporated into many studies.58 In such cases, devices must be standardized and validated to ensure data collection is accurate to minimize the introduction of technical variability, including variability due to skin tone, and consideration should be given to whether these technologies exclude individuals without reliable internet access. In addition, the ability to collect biometric data with smartphones, digital assistants, and other smart technologies and the use of eCohort (online or web‐based cohort) approaches can expand the reach of recruitment efforts and facilitate remote screening.38, 63Social media recruitment can offer a cost‐efficient way of reaching underserved groups and promoting their engagement, providing that ethical issues are considered64, 65; however, potential biases introduced through this form of recruitment also warrant consideration. Social media recruitment may exclude patient groups with limited internet access or low digital health literacy, which often correlate with lower socioeconomic status,64 and may result in less diverse participants, with overrepresentation of White and female individuals and those with higher education and income levels.66Screening of electronic medical records can also facilitate the efficient selection of participants from underserved groups67; however, strategies to mitigate bias due to differences in data capture and access to care for different population groups must be considered.68 The LIFT Diabetes (Lifestyle Intervention for Treatment of Diabetes) trial (NCT01806727) demonstrated that recruitment using electronic medical records, with a predefined target enrollment for underserved populations, was a cost‐ and time‐efficient strategy to recruit a diverse study population.67Deployment of artificial intelligence (AI) platforms could identify additional underserved participants by reducing the number of missed enrollment opportunities,63 and improving the extraction of relevant information (ie, unformatted notes or multimodal analyses such as images) from electronic medical records.69 Similarly, AI may mitigate the impact of variability in data entry, jargon, and diagnostic synonyms, which can confound traditional algorithmic electronic medical record analyses. However, there are limitations to the deployment of AI. For example, if algorithms are trained using data sets based on data in which underserved populations have been poorly represented, then AI has the potential to be biased and, thus, magnify disparities.70, 71 Ethical considerations surrounding the use of AI in clinical trials include the protection of patient privacy, patient consent, and data security.71 Although guidelines and standards to safeguard these areas of concern are being developed by regulatory bodies, AI technologies are constantly evolving.71 Additionally, the financial and time investments required to integrate AI into preexisting clinical trial frameworks may limit AI use.71Finally, increasing the role of community clinics within a decentralized model could offer novel opportunities for community clinicians, providing an essential bridge of trust between trial staff and underserved participants.57Community‐centered research approaches, such as community‐based participatory research and community‐engaged research, can overcome multiple barriers to the participation of underserved groups.63, 72, 73Having a diverse study team can increase the recruitment of participants from diverse backgrounds.30, 38 Cardiovascular clinical trials that are led by women have been shown to be associated with greater levels of recruitment of female participants.74 Conversely, when men are in trial leadership positions, an association with female participant underenrollment has been reported.74, 75 Thus, increasing the proportion of women in clinical trial leadership may increase the enrollment of female trial participants.Reexamining the criteria for “top choice” study sites and PIs could improve study team diversity,38 for example, by placing more value upon institutions with access to underrepresented populations23, 72 and using networks like the Association of Black Cardiologists Clinical Research Network to identify and match investigators to clinical trial opportunities.76Additionally, investment in, and training programs for, women and individuals from racial and ethnic minority groups and increased funding for minority‐serving institutions may increase representation among trial staff and study investigators.38, 72, 77 For example, the National Medical Fellowships Diversity in Clinical Trials Research program is a training program for physicians from ethnic and racial populations that are underrepresented in the medical profession to enable their engagement in clinical trial activities.78 Specifically in the cardiovascular space, Women As One curates programs, events, and grants that support the inclusion of women in cardiovascular clinical trials,79 and the American College of Cardiology's Clinical Trials Research program aims to increase the number of women, Black, Native American, and Hispanic physicians in cardiovascular clinical trial research.80 Additionally, the $24 million American Heart Association Strategically‐Focused Research Network on the Science of Diversity in Clinical Trials81 is funding ongoing projects such as TRAIN (Training Researchers to Advance Inclusion Networks Center)82 and the DIVERSE (Diversity and Inclusion in Cardiovascular Trials Through Enrollment and Education Resulting in Sustainable Equity) Network.83One may reasonably ask how recent changes in federal policy84 might affect recruitment of underrepresented populations and how such efforts will be sustained. Loyalty to science requires inclusion of affected and underrepresented populations into trial cohorts. It is in the long‐term economic interest of industry to perform race, ethnicity, and gender sensitivity analyses and to continue to seek inclusion of underrepresented cohorts to ensure relevance and efficacy of their therapies in those populations. Most important is the assurance that industry has the scientific integrity to ensure that underrepresented populations are seen and adequately studied. Sponsors must continue to support recruitment of those populations with strategies similar to those we have outlined in this article.Community clinicians can engage with their patient base to increase enrollment and retention of underserved populations within clinical trials. Clinicians are well placed to act as official Trial Access Partners to ensure patients are aware of clinical research, understand the implications of participation, and can make an informed decision.85 Separately, offering institutional recognition and awards for the clinicians' role within clinical research could incentivize them to take part.50Inviting advocates for underserved groups to review appropriate trial features can ensure that research is inclusive.30 For example, inviting community members to review existing reimbursement programs and support services could identify participation costs (eg, childcare, transport, time off work).23, 30 Similarly, research materials (ie, enrollment and informed consent materials) could be reviewed to ensure that language matches literacy levels and is culturally sensitive38 and that population‐specific psychological, socioeconomic, and cultural factors are considered.11 Indeed, community–academic partnerships with key stakeholders such as faith‐based organizations and public libraries have resulted in successful interventions, building much‐needed trust in underserved communities.30, 51, 85 For example, screening Black men for hypertension at Black‐owned barbershops resulted in meaningful blood pressure improvements.86We propose that a hub‐and‐spoke clinical trial model that actively engages and uses community‐based clinicians may improve the enrollment of underserved patients.87, 88, 89The premise of our proposed hub‐and‐spoke organizational model in clinical research is the fundamental idea that many underrepresented populations seek care where their trusted providers are. However, from our experience, the burden of additional staffing, regulations, materials, and training required to conduct research activities may serve as barriers to clinical trial participation for community‐based clinical sites. With the hub‐and‐spoke model, we can lessen these burdens by using high‐performing traditional research sites that serve as the central, core, organizational hub, which may themselves be part of decentralized global clinical trial networks. To ensure community‐based satellite locations or spoke sites face no or minimal disruption to clinical workflow and do not incur unreimbursed costs, the hub provides operational processes, leadership, administrative support, and data management, while ensuring regulatory compliance (Figure 3).Minimizing the impact research participation has on the day‐to‐day workload of the spoke site is a key factor for a successful hub‐and‐spoke model. To lessen the burden of patient recruitment on spoke sites, the detection of potential patients for screening can be made more efficient. For example, hub sites can work with billers, coders, and clinical personnel (eg, physician associates and nurse practitioners) to identify clinical markers, including International Classification of Diseases, Tenth Revision (ICD‐10) codes of interest, to detect potential patients for screening. Additionally, the hub site can provide support staff or facilitate AI‐enabled reviews of electronic health records to screen for key inclusion and, particularly, exclusion criteria. Patients who are candidates for screening can then be flagged to treating physicians and referred to patient educators who will provide the patient with the necessary information to make an informed decision on trial participation. In addition, study protocols allowing for community‐based screening (eg, via independent prescreening programs rather than procedures at Visit 1) funded and provided by the central hub may facilitate community physician participation while reducing the burden on patients and offering cost savings to the sponsor.Our proposed model relies on the development of mutually beneficial research partnerships between the hub‐and‐spoke sites. Thus, the often resource‐limited spoke sites, which may treat underserved populations, extend the reach of the hub without the typical financial constraints associated with the expansion of study sites, while maintaining provider–patient relationships.The trust‐based relationship between the hub‐and‐spoke sites, predicated on knowledge and the reputation of potential partners, is key for a successful hub‐and‐spoke trial. Our approach has been to clearly present our decentralized model to potential spoke sites, highlighting the overrepresentation of the provider's patient population in morbidity and mortality of chronic conditions they commonly see, while being underrepresented in clinical trials focused on new therapies for those conditions. Educating community clinicians on clinical trials as a health care option for their patients, and as an additional income source for their practice, may also increase their willingness to participate. However, we believe that purely remunerative and financially based relationships are likely to be viewed poorly by patients.From our experience, when they see themselves in and can communicate with clinical trial staff, patients are more receptive to considering trial participation. It is, therefore, important to use investigators who are known to or have worked in the community in which the spoke site is based. We suggest that competent research champions, who can drive trial participation at their respective organizations, are identified at each spoke site. These individuals may have been engaged in clinical research earlier in their careers and are interested in contributing to current clinical research. These community‐based clinicians could participate as subinvestigators, to reduce their time commitment and allow those without research exposure to garner experience with oversight from a more experienced PI. Alternatively, we propose that community clinicians could participate as PIs with the support of hub centers and flexibility from study funders in regard to prior educational or subinvestigator roles counting as adequate experience. Customized recruitment efforts based on this local expertise can then help overcome site‐specific barriers to representation.Once operational, the hub‐and‐spoke model becomes a template for collaboration on future trials involving investigational products and devices in therapeutic areas other than the cardiovascular space. The model facilitates the primary goal of giving previously underrepresented patients a seat at the research table to ensure clinical research is relevant to them as well as the population at large. The application of this type of organizational model in cardiovascular trial design, incorporating DCT capabilities with a focus on community engagement, could promote diverse research participation.Outside the cardiovascular space, clinical trials using hub‐and‐spoke type models have been implemented in oncology and rare diseases. The well‐established National Cancer Institute Community Oncology Research Program comprises 7 research hubs and 46 community sites of which 14 are designated minority or underserved sites, including >1000 affiliate locations comprising hospitals and private practices.90 As of November 2024, the program's Research Portfolio contained 179 clinical trials including studies of cancer care delivery, prevention, comparative effectiveness, screening, and patient‐reported outcomes.91 Evidence from the National Cancer Institute Community Oncology Research Program suggests that the model is particularly applicable to studies that aim to maximize generalizability rather than those focused on internal validity.92 Similarly, the Influential Medicine Providing Access to Clinical Trials program from the Leukemia and Lymphoma Society funds clinical trials hosted by major cancer centers who partner with community‐based oncologists.93 The use of a hub‐and‐spoke model was trialed in a population with a very rare pediatric neurodegenerative disorder.94 Here, the central hub was responsible for screening, consent, drug dispensing, and tolerability and efficacy assessments while spoke sites performed local safety monitoring. As a result, patients needed to travel to the central hub only at the beginning and end of the study, with no travel‐related missed study visits.94
CLOSING REMARKS
Underserved populations are overrepresented in populations with CVD yet poorly represented within cardiovascular clinical trials. Although the mandatory implementation of diversity action plans for Food and Drug Administration‐registered Phase 3 or pivotal clinical trials is encouraging, for cardiovascular study populations to reflect patients in real‐world practice, holistic approaches are needed to address the complex, interrelated barriers to participation of all patient groups within cardiovascular research. Addressing only logistical barriers ignores the essential issues of time, cultural understanding, and trust. Similarly, although underrepresented patients are more comfortable with their community‐based health care providers, these clinicians often need to be more geographically or institutionally connected with the academic centers conducting clinical research. Additional logistical strategies are still required. Improving clinical trial team diversity and providing better routes to trial participation for community clinicians are important strategies to foster the trust of underserved patients, and community‐based recruitment strategies can effectively engage underrepresented groups within clinical research. DCTs with a community‐centric focus, such as applying the hub‐and‐spoke organizational model, can offer an aggregate solution to overcome many of the individual‐level barriers hindering the representation of these groups within cardiovascular clinical research while providing the necessary infrastructure to help surmount the barriers to the participation of community clinicians.47, 62 As such, it is promising to find that DCT capabilities are currently used more frequently within cardiovascular studies than in any other area of clinical research.95 Ultimately, study sponsors must ensure that these novel trial design features translate into the inclusion of diverse participants that reflect the population with CVD.
Sources of Funding
Medical writing support was funded by Novartis Pharmaceuticals Corporation.
Disclosures
Dr Aggarwal is involved in research funded by the Bristol Myers Squibb‐Pfizer alliance, Novartis, Lexicon, and Amarin, and has previously served as a consultant for Lexicon. Dr Miller is a Medical Advisor to Care Access. Dr Loh is a Senior Consultant and Principal Investigator for Care Access, and Chief Medical Officer of Infermedica. Dr Richmond is a Principal Investigator for ViiV Healthcare and Myovant Sciences.
IL
Dr. Irving Loh
Cardiology · General Non-Invasive CardiologyLos Robles Hospital & Medical Centerirving